CooperCompanies

Q3 2026
Speakers

Sep 9, 2026 · 59 min

PREPARED REMARKS · INFERREDKeys: / search · Space play · ←→ ±10s · [] sections

Prepared remarks

Speaker 0

Unverified voice label

Thank you for standing by. My name is Tina and I will be your conference operator today. At this time, I would like to welcome everyone to the Q3 2026 Cooper Company's Earnings Conference call. All lines have been placed on mute to prevent any background noise. After the speaker's remarks, there will be a question and answer session. To ask a question, simply press star one on your telephone keypad.

To withdraw your question, press star one again. Please limit questions to one and one follow-up. It is now my pleasure to turn the call over to Kim Duncan, Vice President of Investor Relations and Risk Management. Please go
ahead.

Passages & reports (3)
  • Thank you for standing by. My name is Tina and I will be your conference operator today. A…
  • question and answer session. To ask a question, simply press star one on your telephone ke…
  • ahead.

Speaker 1

Unverified voice label

During today's call, we will discuss the results and guidance, the conclusion of the strategic review, and current corporate developments. ?We will then use the remaining time for questions. Our presenters on today's call are Al White, President and Chief Executive Officer, ?and Brian Andrews, Chief Financial Officer. Before we begin, I'd like to remind you that this conference call will contain forward-looking statements, including statements relating to revenue, EPS, cash flow, interest, FX and tax rates, tariffs, and other financial guidance and expectations.

Also, strategic and
operational initiatives, market conditions and trends, and product launches and demand. Forward-looking statements depend on assumptions, data, or methods that may be incorrect or imprecise, and are subject to risks and uncertainties. Events that could cause our actual results and future actions of the company to differ materially from those described in forward-looking statements are set forth under the caption Forward Looking Statements ?in today's earnings release and are described in our SEC filings, including Cooper's Form 10K and Form 10Q filings, all of which are available on our website at CooperCos.com.

Also, as a reminder, the non-GAAP financial information we will provide on this call is provided as a supplement to our GAP information. We
encourage you to consider our results under GAP as well as non-GAP and refer to the reconciliations provided in our earnings release, which is available on the investor relations section of our website under quarterly materials. Should you have any additional questions following the call, please email IR at cooperco.com. ?

And
now I'll turn the call over to Al for his opening remarks.

Passages & reports (12)
  • During today's call, we will discuss the results and guidance, the conclusion of the strat…
  • We
  • will then use the remaining time for questions. Our presenters on today's call are Al Whit…
  • and
  • Brian Andrews, Chief Financial Officer. Before we begin, I'd like to remind you that this …
  • operational initiatives, market conditions and trends, and product launches and demand. Fo…
  • forward-looking statements are set forth under the caption Forward Looking Statements
  • in
  • today's earnings release and are described in our SEC filings, including Cooper's Form 10K…
  • encourage you to consider our results under GAP as well as non-GAP and refer to the reconc…
  • And
  • now I'll turn the call over to Al for his opening remarks.

Speaker 2

Unverified voice label

Thank you, Kim, and welcome everyone to our Q3 earnings call. This quarter included a number of notable developments, including earnings exceeding expectations, record free cash flow, solid fertility growth at Cooper Surgical, and the favorable completion of a significant tax matter. At Cooper Vision, however, we proactively reduced U.S. channel inventory that weighed on our results and will continue to impact Q4. Importantly, our underlying demand in the US remained healthy throughout the quarter, with consumption increasing at a mid-single digit rate, and we're now positioned to enter fiscal 2027 with a healthier channel and stronger foundation.

We're also taking additional steps to strengthen Cooper Vision revenue performance, and I'll speak to these in a moment, but first I want to address the completion of the strategic review, which we announced in a separate press release today. Following a comprehensive evaluation of alternatives, the board has
concluded the strategic review. As part of the process, we conducted a thorough assessment of Cooper Surgical, including a potential sale of the business, where we received significant interest and engaged with numerous parties.

Ultimately, however, the board unanimously determined that shareholders are better served by continued
ownership than by pursuing a transaction at this time. The board and our advisors believe several temporary factors influence valuations laid in the process, including developments related to a competitive entrant in the non hormonal IUD market and the impact of our fertility litigation settlement. These factors contributed to what we believe was a temporary disconnect between Coopersurgical's intrinsic value and the offers received, resulting in proposals that did not adequately reflect the full value and long-term potential of the business.

While the formal strategic review has concluded, our commitment to enhancing shareholder value has not
changed. We gain valuable insights through the process and will intensify our focus on profitable organic growth and disciplined capital allocation, including share repurchases. The board and management will also continue to evaluate opportunities to maximize long-term shareholder value and remain open to strategic alternatives that appropriately recognize the value of our operations.

Turning to the quarter, CooperVision reported revenue of $717 million, essentially flat year over year. AMEA and Asia PAC performed largely in line with our expectations, while the results in the Americas reflected Cooper Vision's U.S. channel
inventory reductions. Moving forward, we see opportunities to strengthen our growth globally through improved execution of our con our contract wins and product launches. And to support this effort, we're investing in expanded sales coverage, increased customer marketing programs, and enhanced commercial execution capabilities, including AI-driven targeting and analytics tools.

These initiatives are already gaining traction in Asia PAC, where our new commercial leadership team is fully in place, and in the U.S., where we're actively expanding our Salesforce organization. These efforts are driving stronger customer engagement,
including within our private label business, where new account wins and SKU introductions are expanding our customer footprint and deepening penetration within existing accounts. We're also continuing to invest in our distribution infrastructure, including a new packaging facility in Puerto Rico that will expand direct to consumer and direct to customer fulfillment capabilities, enhancing service levels, and supporting long-term growth.

All these actions are well underway and position us to drive greater revenue growth in fiscal 2027 and beyond. Turning to products, our flagship My Day franchise continues to perform well, highlighted by double-digit growth
in EMEA and double-digit consumption growth in the Americas. This performance was driven by strong customer partnerships, ongoing expansion in high value categories such as Torics and Multifocals, growing adoption of our premium MyDay Energist offering, and the successful launch of MyDay MySite.

Myday Toric
delivered another quarter of double-digit growth supported by the industry's broadest daily parameter range and the same market-leading toric design as BioAffinity. Myday Toric maintains a meaningful competitive advantage, offering approximately 30% more prescription options than any other daily Toric ones. Myday Multifocal also delivered another quarter of double digit growth, supported by its advanced optical design and easy-to-fit platform. With favorable demographic trends and significant room for category expansion, we continue to view multifocals as one of the most attractive growth opportunities and contact lenses.

And to build
on this, we are preparing to launch MyDay Toric Multifocal, extending our leadership in optics, parameter range, and clinical performance. Finally, MyDay Energist delivered another quarter of double digit growth, reflecting increasing recognition among eye care professionals and wearers of its differentiated combination of premium optics and advanced material technology. For clarity, performance varied by region, with growth in EMEA offset by softer performance in our other two regions.

However, our next generation Clarity Multifocal continues to gain momentum, supported by the same proven fitting design as BioAffinity and MyDay. And we also recently
completed ?the Clarity Family launch in Japan, and initial customer response has been encouraging. Turning to Bioaffinity, strength in AMIA and within our market-leading made-to-order portfolio, including Tortifocals and Extended Ranges, was offset by the inventory moves in the U.S., resulting in a flat quarter.

Regarding myopia management, my site delivered another strong quarter with 20% organic growth. AMEA and the Americas led performance while softness in China weighed on Asia Pac. Although this was partially offset by growing momentum in Japan following our MySite launch earlier this year. In EMIA, growth was supported by the
ongoing launch of MyDay MySite with back to school campaigns highlighting the benefits of a silicone hydrogel offering.

Canada also launched Myday MySite in August, and customer feedback has been excellent. Importantly, in these markets that have Myday MySite, the Myday platform now supports patients across every stage of life, from
myopia management in children through spherical, torque, multifocal, and premium lifestyle offerings in adulthood. Looking ahead, we expect my site growth to be in the low teens in Q4 against a difficult prior year comparison, resulting in roughly 20% growth for this full year and setting the stage for a promising 2027 supported by continued momentum in existing markets and the upcoming launch of My Day MySite Toric.

Lastly, on Vision, we're accelerating programs tied to new product development, and that ties nicely in with the opening of our global vision center in the UK later this month.

Passages & reports (24)
  • Thank you, Kim, and welcome everyone to our Q3 earnings call. This quarter included a numb…
  • reduced U.S. channel inventory that weighed on our results and will continue to impact Q4.…
  • healthier channel and stronger foundation. We're also taking additional steps to strengthe…
  • concluded the strategic review. As part of the process, we conducted a thorough assessment…
  • ownership than by pursuing a transaction at this time. The board and our advisors believe …
  • contributed to what we believe was a temporary disconnect between Coopersurgical's intrins…
  • changed. We gain valuable insights through the process and will intensify our focus on pro…
  • alternatives that appropriately recognize the value of our operations. Turning to the quar…
  • inventory reductions. Moving forward, we see opportunities to strengthen our growth global…
  • execution capabilities, including AI-driven targeting and analytics tools. These initiativ…
  • including within our private label business, where new account wins and SKU introductions …
  • customer fulfillment capabilities, enhancing service levels, and supporting long-term grow…
  • in EMEA and double-digit consumption growth in the Americas. This performance was driven b…
  • delivered another quarter of double-digit growth supported by the industry's broadest dail…
  • Multifocal also delivered another quarter of double digit growth, supported by its advance…
  • on this, we are preparing to launch MyDay Toric Multifocal, extending our leadership in op…
  • advanced material technology. For clarity, performance varied by region, with growth in EM…
  • completed
  • the
  • Clarity Family launch in Japan, and initial customer response has been encouraging. Turnin…
  • Regarding myopia management, my site delivered another strong quarter with 20% organic gro…
  • ongoing launch of MyDay MySite with back to school campaigns highlighting the benefits of …
  • myopia management in children through spherical, torque, multifocal, and premium lifestyle…
  • the stage for a promising 2027 supported by continued momentum in existing markets and the…

This state-of-the-art facility brings together RD, our next gen technical manufacturing teams, and our commercial teams in a single integrated environment. The investment will accelerate innovation, enhance collaboration, and enable greater speed to market as we capitalize on one standardized manufacturing platform for all future product development. Starting to Cooper Surgical revenue was $349 million, up 3% organically. Within this, fertility delivered another solid quarter, growing 5% to $141 million.

By product category, fertility growth was driven by broad-based strength across our leading global portfolio of products
and services, partially offset by softer capital equipment sales following a very strong prior quarter. Genomics was a notable contributor, driven by robust global demand, along with continued adoption of Witness, our automated laboratory management platform. Performance was further supported by new clinic wins, expansion within existing accounts, and increasing uptake of recently launched products and services, all resulting in continued global market share gains.

Geographically, growth was led by the Americas, where we continued to gain share, while MEA and Asia PAC remained mixed, as strength across several markets was offset by
macro headwinds in the Middle East and China. Stepping back, the long-term fundamentals of the global fertility market remain compelling. Delayed family formation, expanding access to care, increasing treatment utilization, and continued investments by fertility clinics supports durable long-term growth.

Passages & reports (5)
  • This state-of-the-art facility brings together RD, our next gen technical manufacturing te…
  • development. Starting to Cooper Surgical revenue was $349 million, up 3% organically. With…
  • and services, partially offset by softer capital equipment sales following a very strong p…
  • wins, expansion within existing accounts, and increasing uptake of recently launched produ…
  • macro headwinds in the Middle East and China. Stepping back, the long-term fundamentals of…

Government support for family building also remains favorable. Earlier this year, Denmark expanded publicly funded fertility coverage from three cycles to six. Japan's reimbursement framework continues to improve access and affordability for assisted reproductive technologies. In the Middle East, investments in reproductive health care infrastructure continue to support growth in the UAE fertility market. And in California, large group health plans are now required to provide coverage for IVF and certain infertility treatments, representing another meaningful step towards expanding patient access. ?

To
conclude on fertility, we expect continued strength, including a solid fourth quarter supported by healthy market trends and growing momentum across our innovation pipeline, particularly in genomics. Turning to office and surgical, revenue was 208 million up 2%. Medical devices grew 4%, driven by continued strength in our surgical OBGYN and specialty device portfolios, while Paraguard revenue was flat. Finally, Cooper Surgical delivered another quarter of strong operating leverage, reflecting the improved profitability and cash generation of our streamlined business model.

Passages & reports (5)
  • Government support for family building also remains favorable. Earlier this year, Denmark …
  • infrastructure continue to support growth in the UAE fertility market. And in California, …
  • To
  • conclude on fertility, we expect continued strength, including a solid fourth quarter supp…
  • our surgical OBGYN and specialty device portfolios, while Paraguard revenue was flat. Fina…

Speaker unclear

?Now,

Passages & reports (1)
  • Now,

Speaker 2

before turning the call over to Brian, let me leave you with a few key takeaways. At Cooper Vision, underlying demand remains healthy and our long-term growth drivers remain firmly in place, including continued momentum in my day, strong demand for our toric and multifocal lenses, and the ongoing success of my site. At Cooper Surgical, we remain excited about the fertility market and the opportunities ahead supported by our strong RD pipeline.

Finally, while the strategic review process was extremely challenging for our teams, it provided valuable insights and we believe we are well positioned to execute our plans and deliver strong performance in
2027 and beyond. With that, I'll turn the call over to Brian.

Passages & reports (3)
  • before turning the call over to Brian, let me leave you with a few key takeaways. At Coope…
  • Surgical, we remain excited about the fertility market and the opportunities ahead support…
  • 2027 and beyond. With that, I'll turn the call over to Brian.

Speaker unclear

?Thank

Passages & reports (1)
  • Thank

Speaker 2

you, Al, and good afternoon, everyone. Most of my commentary will be on a non gap basis, so please refer to today's earnings release for reconciliation of GAAP to non-GAAP results. ?For the third fiscal quarter, consolidated revenue was $1.066 billion, increasing approximately 1% on both a reported and organic basis. Gross margin was 66.7% down 60 basis points year over year. This was largely in line with our expectations, reflecting higher costs ?and foreign exchange headwinds.

Operating margins increased 30 basis points year over year to 26.3%, driven by ongoing productivity improvements. Interest expense was $21.5 million,
?and our non GAAP effective tax rate was 15.3%. Before moving to earnings, I want to spend a moment on taxes. During the quarter, we recognized a sizable discrete tax benefit of approximately $307 million following the favorable completion of HMRC's examination of our fiscal 2021

Passages & reports (9)
  • you, Al, and good afternoon, everyone. Most of my commentary will be on a non gap basis, s…
  • For
  • the third fiscal quarter, consolidated revenue was $1.066 billion, increasing approximatel…
  • reflecting higher costs
  • and
  • foreign exchange headwinds. Operating margins increased 30 basis points year over year to …
  • and
  • our non GAAP effective tax rate was 15.3%. Before moving to earnings, I want to spend a mo…
  • HMRC's examination of our fiscal 2021

Speaker unclear

?transfer of

Passages & reports (1)
  • transfer of

Speaker 3

Unverified voice label

intellectual property and related assets to the UK. Importantly, ?the closure of the

Passages & reports (3)
  • intellectual property and related assets to the UK. Importantly,
  • the
  • closure of the

Speaker 2

examination provides clarity and

Passages & reports (1)
  • examination provides clarity and

Speaker 3

certainty

Passages & reports (1)
  • certainty

Speaker 2

around

Passages & reports (1)
  • around

Speaker unclear

?a

Passages & reports (1)
  • a

Speaker 3

matter that has been under review for several years and is now expected to extend meaningful non-GAP tax benefits for at least an additional 10 years. Turning to earnings, non-GAP EPS increased 4% to $1.15, including approximately 3 cents from tariff refunds based on approximately 193 million diluted shares outstanding. This marks our 11th consecutive quarter exceeding consensus earnings expectations, reflecting disciplined execution, strong operational management, ?and the benefits of the reorganization completed in the fourth quarter of last year.

Turning to cash flow, we generated free cash flow of $273 million, the highest quarterly free cash flow in Cooper's history. This was driven by strong operating performance,
improving working capital trends, and declining CapEx, all of which has contributed to year to date free cash flow of $528 million, up 86% from last year. This performance reinforces our confidence in achieving our goal of generating $2.2 billion of cumulative free cash flow in fiscal 26 to 2028.

Supported by this strong cash generation, we repurchased $339 million of shares during the quarter, bringing fiscal year-to-date repurchases to $445 million,
while maintaining leverage below two times. Given our confidence in the business and commitment to capital returns, the board approved a $1 billion increase to our share repurchase authorization, bringing a remaining capacity to approximately $1.5 billion for future repurchases. Turning to guidance, ?for Q4, we expect consolidated revenue of $1.057 billion to $1.08 billion, representing organic growth of 0 to 2%.

Passages & reports (10)
  • matter that has been under review for several years and is now expected to extend meaningf…
  • refunds based on approximately 193 million diluted shares outstanding. This marks our 11th…
  • and
  • the benefits of the reorganization completed in the fourth quarter of last year. Turning t…
  • improving working capital trends, and declining CapEx, all of which has contributed to yea…
  • billion of cumulative free cash flow in fiscal 26 to 2028. Supported by this strong cash g…
  • while maintaining leverage below two times. Given our confidence in the business and commi…
  • billion for future repurchases. Turning to guidance,
  • for
  • Q4, we expect consolidated revenue of $1.057 billion to $1.08 billion, representing organi…

Speaker unclear

?We

Passages & reports (1)
  • We

Speaker 3

expect cooperation revenue of $692 million to $706 million, down 2% to flag organically. Within this, we expect regional performance trends to be broadly consistent with Q3, ?with the Americas reflecting the impact of channel inventory actions, EMEA delivering another solid quarter, ?and Asia PAC continuing to face near-term challenges. ?We expect CUPA surgical revenue of $364 million to $374 million, representing organic growth of four to six percent.

Passages & reports (7)
  • expect cooperation revenue of $692 million to $706 million, down 2% to flag organically. W…
  • with
  • the Americas reflecting the impact of channel inventory actions, EMEA delivering another s…
  • and
  • Asia PAC continuing to face near-term challenges.
  • We
  • expect CUPA surgical revenue of $364 million to $374 million, representing organic growth …

Speaker unclear

?We

Passages & reports (1)
  • We

Speaker 3

expect interest expense of roughly $25 million, reflecting incremental borrowing associated with share repurchases and litigation related payments. We expect ?the Q4 non-GAP effective tax rate to be roughly 16%, resulting in non-GAP EPS of $1.05 to $1.09. We expect around $170 million of free cash flow, excluding litigation-related payments of roughly $272 million.

Passages & reports (3)
  • expect interest expense of roughly $25 million, reflecting incremental borrowing associate…
  • the
  • Q4 non-GAP effective tax rate to be roughly 16%, resulting in non-GAP EPS of $1.05 to $1.0…

Our foreign exchange assumptions are largely unchanged from last quarter. In summary, we expect Q4 to be broadly similar to Q3, with the primary differences being greater commercial investments in Kubervision, additional FX headwinds, and lower tariff refunds, which will pressure gross and operating margins. Looking ahead to fiscal 2027, it's too early to provide guidance other than to note that our scheduled guilty increase of roughly 2% in the U.S.

taxation of foreign earnings
?will impact our non-gap effective tax rate. All else being equal, we expect this increase, we expect this to increase our tax rate from roughly 15.5 this year to roughly 17.5 in fiscal 2027.

Passages & reports (4)
  • Our foreign exchange assumptions are largely unchanged from last quarter. In summary, we e…
  • operating margins. Looking ahead to fiscal 2027, it's too early to provide guidance other …
  • will
  • impact our non-gap effective tax rate. All else being equal, we expect this increase, we e…

To conclude, despite actions we took within Cooper Vision that weighed on performance, we delivered another quarter of earnings above expectations and record free cash flow. We also achieved a favorable resolution of HMRC's examination of our 2021 UK tax planning initiative and returned significant capital to shareholders. At the same time, we are intensifying our efforts to drive organic growth through new commercial investments ?and a more streamlined operating ?model.

Together, these initiatives position us to accelerate growth, expand profitability,
?and increase cash generation in the years ahead. Supported by a strong balance sheet and disciplined capital allocation framework, we remain confident in our ability to create meaningful long-term value for shareholders. With that, I will turn the call over to the operator for questions.

Passages & reports (8)
  • To conclude, despite actions we took within Cooper Vision that weighed on performance, we …
  • shareholders. At the same time, we are intensifying our efforts to drive organic growth th…
  • and
  • a more streamlined operating
  • model.
  • Together, these initiatives position us to accelerate growth, expand profitability,
  • and
  • increase cash generation in the years ahead. Supported by a strong balance sheet and disci…

Speaker 0

At this time to ask a question, simply press star one on your telephone keypad. Our first question comes from the line of John Block.

Passages & reports (1)
  • At this time to ask a question, simply press star one on your telephone keypad. Our first …

Questions & answers

Speaker 4

Unverified voice label

Thanks. ?Thanks, guys. Good afternoon. So Al, previously the fiscal 2H26 CBI growth was expected to be up roughly 4%. Now fiscal 2H is expected to be flattish. And you made some comments around consumption. I just want to be clear is the entirety of that revision inventory related as you did pull out consumption and mid single digit growth specific to the quarter? I'm just wondering if that consumption assumption was also applies to fiscal four Q.

So maybe you can just tease out the plus four to zero in fiscal two H, how much of that is you know D stock versus underlying fundamentals?

Passages & reports (4)
  • Thanks.
  • Thanks,
  • guys. Good afternoon. So Al, previously the fiscal 2H26 CBI growth was expected to be up r…
  • pull out consumption and mid single digit growth specific to the quarter? I'm just wonderi…

Speaker unclear

?Yeah,

Passages & reports (1)
  • Yeah,

Speaker 2

John, it's all D stock. So the the consumption in the U.S. market here has been running pretty steady all year in the mid single digits. Um it was it did in Q3 and it did in the first month of this quarter. So I would expect consumption to remain as is, meaning the entire um uh reason for the reduction in the the uh uh revenue guidance for Cooper Vision was tied to just channel inventory.

That's

Passages & reports (2)
  • John, it's all D stock. So the the consumption in the U.S. market here has been running pr…
  • um uh reason for the reduction in the the uh uh revenue guidance for Cooper Vision was tie…

Speaker unclear

?it.

Passages & reports (1)
  • it.

Speaker 4

Okay. So um thanks for the clarity there. I I guess if there's just an obvious follow-up, which would be if you're exiting this year at flat off of pretty modest cobs, just any high-level thoughts on 2027 CVI? In other words, do we think it can go back to mid-single digits as it would revert back to consumption? Or should we think, hey, ?you know, you're going to be below market this year.

Do we think below market next year, really until some new products start to come out of the innovation hub? Thanks, guys.

Passages & reports (4)
  • Okay. So um thanks for the clarity there. I I guess if there's just an obvious follow-up, …
  • revert back to consumption? Or should we think, hey,
  • you know,
  • you're going to be below market this year. Do we think below market next year, really unti…

Speaker 2

Yeah, um a couple things on that. You know, I mean some of the moves that we're making that you see here in the U.S. with respect to the channel inventory are one that's impacting us. The another one that's impacting us has been for a little bit and will to end this year is some of the portfolio rationalization we're doing with our legacy hydrogels.

Our legacy hydrogels were down double digit across the board as we continue to kind of move away from those products. That work we're going to get completed here in our fiscal Q4, and that'll put us in significantly better footing back to kind
of Cooper Vision of old or normal Cooper Vision, if you will, as uh as we get into 2027.

Passages & reports (3)
  • Yeah, um a couple things on that. You know, I mean some of the moves that we're making tha…
  • some of the portfolio rationalization we're doing with our legacy hydrogels. Our legacy hy…
  • of Cooper Vision of old or normal Cooper Vision, if you will, as uh as we get into 2027.

Speaker 4

Thank

Passages & reports (1)
  • Thank

Speaker unclear

?you.

Passages & reports (1)
  • you.

Speaker 0

Your next question is from the line of Jeff Johnson. Please go ahead.

Passages & reports (1)
  • Your next question is from the line of Jeff Johnson. Please go ahead.

Speaker 5

Unverified voice label

Hey, thanks. Good afternoon, guys. Uh let me just stick on maybe uh that same line of question John was just asking, and then I've got one other follow-up as well. But on the D-stock itself, uh you Al, you made uh may have just answered the question on some of the legacy hydrogel stuff, but what is actually driving that D stock and how how do we think about, you know, the risk that that bleeds over into the early part of 27?

Have you ring fenced that uh you know fairly confidently that this is a a a fiscal Q4 should be the last of it, or how
do we think about like the early 27 potential impact and then one follow-up? Thanks.

Passages & reports (3)
  • Hey, thanks. Good afternoon, guys. Uh let me just stick on maybe uh that same line of ques…
  • but what is actually driving that D stock and how how do we think about, you know, the ris…
  • do we think about like the early 27 potential impact and then one follow-up? Thanks.

Speaker 2

Yeah, I w we have ring fenced that, so to speak. Um we we have gone through that deep, deeply and dug into all the details and where the channel inventory is and what's happening. A lot of it was tied to bioaffinity, Um, but there was other, there was stuff with dailies, and there was definitely, definitely inventory that was tied to some legacy hydrogels and some of those kind of products.

But we're we're going to get that behind us here in Q4, at least the vast majority of it. Same with the rationalization and the moves in Asia Pack so that we get back in good footing
and get back to normal, if you will, in 2027.

Passages & reports (3)
  • Yeah, I w we have ring fenced that, so to speak. Um we we have gone through that deep, dee…
  • was definitely, definitely inventory that was tied to some legacy hydrogels and some of th…
  • and get back to normal, if you will, in 2027.

Speaker 5

Okay. I I guess I'll just push you a little bit on that. Just, you know, I hear by hearing your answer there w ?the different lines that de stocked, but but why are they desking? Has end markets slowed? Did you guys have too much inventory in the ch channel uh from past efforts to kind of prop up numbers? Is it uh you know competitive uh new product launches that are just requiring less Cooper vision inventory, just anything there.

And then you mentioned APAC there at the end of your answer. I guess my other question was going to be on APAC. Last quarter you talked about you know fiscal Q three being the last of the uh Cooper specific issues there and and and you felt like the market was kind
of flat, maybe down a little bit in Asia PAC, and that you could get back towards that market rate in Q4.

Has that assumption now changed? And if so, maybe why? Thank

Passages & reports (5)
  • Okay. I I guess I'll just push you a little bit on that. Just, you know, I hear by hearing…
  • the
  • different lines that de stocked, but but why are they desking? Has end markets slowed? Did…
  • anything there. And then you mentioned APAC there at the end of your answer. I guess my ot…
  • of flat, maybe down a little bit in Asia PAC, and that you could get back towards that mar…

Speaker unclear

?you. Yeah,

Passages & reports (1)
  • you. Yeah,

Speaker 2

I'll touch that one first, Jeff. So on Asia Pack, I would say that market's actually stabilizing to getting a little bit better, which is which is great news.

Passages & reports (1)
  • I'll touch that one first, Jeff. So on Asia Pack, I would say that market's actually stabi…

Speaker 2

That we were finishing up the a lot of the rationalization work and positioning work and so forth with respect to the legacy hydrogels and clarity entering. So that's what I'm kind of referencing, saying that similar to last quarter, we're gonna finish that up. We were probably halfway through it or maybe a little bit more. We took another chunk out of it here in Q three and we'll finish that in Q4.

Um so I think you'll get Asia Pac being back to relatively back to normal like as as we start the year off. Um if I look at the channel inventory in the US, you know,
we see channel inventory kind of go up and go down, and we've seen that many times over the years. We did have channel inventory trend higher here, and that's been for a couple different reasons.

Some of it was people buying before price increases, some of it's been consolidation activity, some of it's been
buying before things like IT upgrades go in. Most recently here, in like Q1 and Q2, you saw channel inventory move up associated with buying, tied to some of the new private label contracts we won, and that was pushing up inventory without offsetting it in a different spot.

So this was
something that you know we took a look at, a long and hard look at and said, hey, uh normally what would happen here and what's happened in the past is that channel inventory would burn itself off over the next year and a half or something like that, and you'd move back to normal.

Passages & reports (5)
  • That we were finishing up the a lot of the rationalization work and positioning work and s…
  • bit more. We took another chunk out of it here in Q three and we'll finish that in Q4. Um …
  • we see channel inventory kind of go up and go down, and we've seen that many times over th…
  • buying before things like IT upgrades go in. Most recently here, in like Q1 and Q2, you sa…
  • something that you know we took a look at, a long and hard look at and said, hey, uh norma…

And rather than doing that and dealing with that as we have many times over the 20 plus years I've been here, we decided to go ahead and proactively accelerate that and just get that taken care of right now in Q3 and Q4 so that we won't have that overhang at all next year. And we'll go back to growth uh tied to consumption.

Passages & reports (2)
  • And rather than doing that and dealing with that as we have many times over the 20 plus ye…
  • And we'll go back to growth uh tied to consumption.

Speaker 5

Thank

Passages & reports (1)
  • Thank

Speaker unclear

?you.

Passages & reports (1)
  • you.

Speaker 0

Your next question is from Larry Biggleson. Please go ahead.

Passages & reports (1)
  • Your next question is from Larry Biggleson. Please go ahead.

Speaker 6

Unverified voice label

Hi, ?it's a lay on for Larry. Thanks for taking the questions. Um can you quantify the impact of the US inventory reduction in fiscal Q three. I mean, you talked about consumption being in the middle mid-single digit. So is that difference versus what you reported for CVA? Is that the magnitude of inventory reduction in the quarter? And what's assumed about the impact of the inventory in fiscal Q4?

And I have a follow-up.

Passages & reports (4)
  • Hi,
  • it's
  • a lay on for Larry. Thanks for taking the questions. Um can you quantify the impact of the…
  • inventory reduction in the quarter? And what's assumed about the impact of the inventory i…

Speaker 2

Yeah, so Leigh, yeah, just to

Passages & reports (1)
  • Yeah, so Leigh, yeah, just to

Speaker 3

be clear on that, the Americas would have reported

Passages & reports (1)
  • be clear on that, the Americas would have reported

Speaker 2

growth around

Passages & reports (1)
  • growth around

Speaker 3

five percent in Q three if we

Passages & reports (1)
  • five percent in Q three if we

Speaker 2

hadn't

Passages & reports (1)
  • hadn't

Speaker 3

made the inventory

Passages & reports (1)
  • made the inventory

Speaker 2

reduction moves.

Passages & reports (1)
  • reduction moves.

Speaker 3

we would envision

Passages & reports (1)
  • we would envision

Speaker 2

Q4

Passages & reports (1)
  • Q4

Speaker 3

is

Passages & reports (1)
  • is

Speaker 2

actually going

Passages & reports (1)
  • actually going

Speaker 3

to be pretty similar to

Passages & reports (1)
  • to be pretty similar to

Speaker 2

what Q3 was, I would say, for the Americas, for EMEA, and Asia PAC. So you'll have a similar inventory

Passages & reports (1)
  • what Q3 was, I would say, for the Americas, for EMEA, and Asia PAC. So you'll have a simil…

Speaker 3

reduction that

Passages & reports (1)
  • reduction that

Speaker 2

will occur in Q4 in the US.

Passages & reports (1)
  • will occur in Q4 in the US.

Speaker 6

Okay, so the magnitude should be similar, you're saying, for the inventory reduction in Q4?

Passages & reports (1)
  • Okay, so the magnitude should be similar, you're saying, for the inventory reduction in Q4…

Speaker 2

That's

Passages & reports (1)
  • That's

Speaker unclear

?right.

Passages & reports (1)
  • right.

Speaker 6

Okay, thanks. And then my other question is around the PL for Q4. So I'm backing into an operating margin somewhere in the mid 20%, just based on your EPS guidance. Um, that would be down sequentially as well as year over year. So one, just want to check that. And two, what's driving that lower margin? Um, you have a tariff benefit in fiscal Q three. ?

Um,
is it all inventory related? ?Um, or are there other factors in there? And if there's anything in your EPS guide about additional buyback in fiscal Q4. Thank

Passages & reports (6)
  • Okay, thanks. And then my other question is around the PL for Q4. So I'm backing into an o…
  • lower margin? Um, you have a tariff benefit in fiscal Q three.
  • Um,
  • is it all inventory related?
  • Um,
  • or are there other factors in there? And if there's anything in your EPS guide about addit…

Speaker unclear

?you.

Passages & reports (1)
  • you.

Speaker 2

Sure. So nothing

Passages & reports (1)
  • Sure. So nothing

Speaker 3

in the guidance with respect to

Passages & reports (1)
  • in the guidance with respect to

Speaker 2

buybacks. Answer that one. When you look at your operating margin thinking, you're you're in the ballpark, and Brian kind of touched on it, the factors being tariffs being FX is a little bit more negative, and then being investments in Cooper Surgical. So we have started that investment activity in Cooper Surgical. We started it during Q3, actually. So you're gonna we're starting to see the impact of that.

Now we'll get a return on that, of course, next year, but you're starting to see the impact this

Passages & reports (2)
  • buybacks. Answer that one. When you look at your operating margin thinking, you're you're …
  • started it during Q3, actually. So you're gonna we're starting to see the impact of that. …

Speaker unclear

?year.

Passages & reports (1)
  • year.

Speaker 0

Your next question comes from the line of adjacent Bednar, please go ahead.

Passages & reports (1)
  • Your next question comes from the line of adjacent Bednar, please go ahead.

Speaker unclear

?Hey, good afternoon.

Passages & reports (1)
  • Hey, good afternoon.

Speaker 7

Unverified voice label

Thanks for taking the questions. Um sorry to hammer here and be a dead horse, but I'm gonna ask another one on the D stock. Just a question on your confidence ?that this is just an America's issue that won't bleed over to EMIA and maybe talk about how America's is benchmarked versus AMIA so we can have confidence uh that this issue just doesn't extend over to that geography and you know visibility that you have into the channel there.

And you know, maybe why not
uh maybe take it from a different perspective, why not make some moves in in EMIA so uh that that channel or that geography is on a on healthy footing heading it heading into fiscal twenty seven?

Passages & reports (4)
  • Thanks for taking the questions. Um sorry to hammer here and be a dead horse, but I'm gonn…
  • that
  • this is just an America's issue that won't bleed over to EMIA and maybe talk about how Ame…
  • uh maybe take it from a different perspective, why not make some moves in in EMIA so uh th…

Speaker 2

Yeah, so the difference is

Passages & reports (1)
  • Yeah, so the difference is

Speaker 3

AMIA is a a much

Passages & reports (1)
  • AMIA is a a much

Speaker 2

greater subscription based market.

Passages & reports (1)
  • greater subscription based market.

Speaker 3

Uh

Passages & reports (1)
  • Uh

Speaker 2

we're actually seeing the US move in that direction. That's one of the things I was talking about with the new Puerto Rico facility is that you're seeing more direct to consumer shipping activity. You see that in AMIA right now. Um that kind of prevents you from having like these inventory, these big inventory swings and so forth. So we just don't really see that in AMIA.

I mean you can get it with customers and so forth, of course, right? But but we just don't have that happening in AMIA. So I'm not worried about about it in that region. Um when you look at the US, it's
centered on a relatively small number of um of uh uh players, if you will, between distributors and some online e-commerce. So it's pretty easy to straightforward tackle it.

And and that's what we did. And it's pretty easy to get an understanding about how much channel inventory is out
?there, um, what levels people need to hold in order to maintain customer service requirements and so forth. And you can look at that delta, and that's how you ring fence it, so to speak, to to be able to say, hey, I can do this and I can quantify it within a couple quarter period.

Passages & reports (5)
  • we're actually seeing the US move in that direction. That's one of the things I was talkin…
  • swings and so forth. So we just don't really see that in AMIA. I mean you can get it with …
  • centered on a relatively small number of um of uh uh players, if you will, between distrib…
  • there,
  • um, what levels people need to hold in order to maintain customer service requirements and…

Speaker 7

All right. All right, that's helpful. And then Al or Brian, you you I think you both discussed today investments in CPI sales, marketing, and RD. Usually that type of approach that's needed to accelerate growth comes at the expense of margins, even if temporarily, but it doesn't seem like that's what you're suggesting today. So can you talk a bit more about the investment buckets and then your confidence level in posting margin improvement next year in the face of this spending, uh, knowing that we've already gone through some cost down efforts coming into this fiscal

Passages & reports (2)
  • All right. All right, that's helpful. And then Al or Brian, you you I think you both discu…
  • So can you talk a bit more about the investment buckets and then your confidence level in …

Speaker unclear

?year.

Passages & reports (1)
  • year.

Speaker 3

Sure. Uh I'll take that one. Yeah. So the the commercial investments in in Salesforce expansion, ?you know, marketing programs, new product development, those, you know, the Salesforce ads are are, you know, tend to be a short-term detriment to margins. You know, as we as we bring in those Salesforce, train them up, get them deployed, you know, that'll, you know, that'll be a short-term detriment, you know, for longer term benefits.

So, you know, we are addressing Salesforce expansion across our businesses, across regions. So I'm not going to get into 2027 guidance right now. Obviously, we've been leveraging parts of the PL and we continue to leverage that, and you see that drop through in profitability and earnings. But in terms of next year, you
know, we'll get into next year in December, in terms of how that's going to impact how the the moves to drive long-term sustainable organic growth will impact our year, including gating in in December.

Passages & reports (5)
  • Sure. Uh I'll take that one. Yeah. So the the commercial investments in in Salesforce expa…
  • you know,
  • marketing programs, new product development, those, you know, the Salesforce ads are are, …
  • So, you know, we are addressing Salesforce expansion across our businesses, across regions…
  • know, we'll get into next year in December, in terms of how that's going to impact how the…

Speaker 0

Your next question is from the line of Robbie Marcus. Please go ahead.

Passages & reports (1)
  • Your next question is from the line of Robbie Marcus. Please go ahead.

Speaker unclear

?Oh great. Uh thanks for taking the question.

Passages & reports (1)
  • Oh great. Uh thanks for taking the question.

Speaker 7

Two from me.

Passages & reports (1)
  • Two from me.

Speaker 6

One, ?what when

Passages & reports (3)
  • One,
  • what
  • when

Speaker 7

did you first start um the des stocking? And you know, w where are you now with channel inventory? I don't know if you measure in days in the US. Where was it in the beginning of the year and where was it last year? just so we could get a sense. ?And then I have a follow-up.

Passages & reports (3)
  • did you first start um the des stocking? And you know, w where are you now with channel in…
  • And
  • then I have a follow-up.

Speaker 3

Yeah, so I would say, well, I I don't want

Passages & reports (1)
  • Yeah, so I would say, well, I I don't want

Speaker 2

to go kind of back and like build out by a quarter. I don't think that's going to do anybody any good. Um but I look at it and say that uh we're

Passages & reports (1)
  • to go kind of back and like build out by a quarter. I don't think that's going to do anybo…

Speaker 3

I

Passages & reports (1)
  • I

Speaker 2

would say halfway through it. We did it here in Q3 and we're going to do the other half of it in Q4.

Passages & reports (1)
  • would say halfway through it. We did it here in Q3 and we're going to do the other half of…

Speaker 7

Okay, but you're not willing to say if

Passages & reports (1)
  • Okay, but you're not willing to say if

Speaker 2

this year ran at above average or below average or ?well this year

Passages & reports (3)
  • this year ran at above average or below average or
  • well
  • this year

Speaker 3

ran above has run above average. As

Passages & reports (1)
  • ran above has run above average. As

Speaker 2

I mentioned, like there

Passages & reports (1)
  • I mentioned, like there

Speaker 3

was stocking associated with some of the new private

Passages & reports (1)
  • was stocking associated with some of the new private

Speaker 2

label contracts we've won as an example that has pushed up distributor inventory that we saw in Q1 and Q2 as an example. Great. And then I I know you're not giving 27 guidance. I I think we're ?all grappling with so much of the uh the movement and and um changes in guidance

Passages & reports (3)
  • label contracts we've won as an example that has pushed up distributor inventory that we s…
  • all
  • grappling with so much of the uh the movement and and um changes in guidance

Speaker 7

throughout

Passages & reports (1)
  • throughout

Speaker 2

the the past several quarters. Um

Passages & reports (1)
  • the the past several quarters. Um

Speaker 7

but maybe are are you okay with leveraged EPS growth next year and maybe like a a three to four percent top line um ?you know still a touch lower than where the street is or does the uh the step up in tax preclude the ability to get leveraged EPS growth? Thanks a

Passages & reports (3)
  • but maybe are are you okay with leveraged EPS growth next year and maybe like a a three to…
  • you
  • know still a touch lower than where the street is or does the uh the step up in tax preclu…

Speaker unclear

?lot

Passages & reports (1)
  • lot

Speaker 3

um yeah it's it's for as much as I'd like to to give commentary on next year I'm just not going to get into it right now, not until December.

Passages & reports (1)
  • um yeah it's it's for as much as I'd like to to give commentary on next year I'm just not …

Speaker 0

Your next question is from Joanne Winch. Please go ahead.

Passages & reports (1)
  • Your next question is from Joanne Winch. Please go ahead.

Thank you so

Passages & reports (1)
  • Thank you so

Speaker unclear

?much for taking

Passages & reports (1)
  • much for taking

Speaker 6

the question, and I'm going to try it from a different angle.

Passages & reports (1)
  • the question, and I'm going to try it from a different angle.

Speaker 0

If

Passages & reports (1)
  • If

Speaker 6

the third quarter and the fourth quarter are negatively being impacted by the channel inventory and the contact loans market is growing four ?to six percent. Is it reasonable to assume that next year you can ?grow within the ?range of the

Passages & reports (7)
  • the third quarter and the fourth quarter are negatively being impacted by the channel inve…
  • to six
  • percent. Is it reasonable to assume that next year you can
  • grow within
  • the
  • range of
  • the

Speaker unclear

?market?

Passages & reports (1)
  • market?

Speaker 2

Uh yes, that is reasonable. Um I would say a couple of things, Joanne. Let me give just a little color on that because your question is very fair. Like we don't have a manufacturing issue. Our team is strong, we're producing product. We don't have a distribution or logistics issue. We don't have a problem winning contracts. We won a number of contracts. Where we've struggled is execution at the end of that, is actually executing and delivering revenues.

So it's kind of like we're moving through this entire process, which is one of the things that's kept me optimistic. But then we're not converting at the very last
stage of that. That actual commercial execution is where the struggling has happened. So this Salesforce execution, this this additional marketing, um, the the intensity around that kind of stuff and targeting and so forth is the key to

Passages & reports (3)
  • Uh yes, that is reasonable. Um I would say a couple of things, Joanne. Let me give just a …
  • problem winning contracts. We won a number of contracts. Where we've struggled is executio…
  • stage of that. That actual commercial execution is where the struggling has happened. So t…

Speaker 3

success for

Passages & reports (1)
  • success for

Speaker 2

us. Right? It's not

Passages & reports (1)
  • us. Right? It's not

Speaker 3

products, it's not getting

Passages & reports (1)
  • products, it's not getting

Speaker 2

customer

Passages & reports (1)
  • customer

Speaker 3

products, it's not winning contracts, it's executing

Passages & reports (1)
  • products, it's not winning contracts, it's executing

Speaker 2

at the end on the sales. We don't have enough salespeople out there. Like hindsight's 2020, we should have moved faster on this. Like we don't have enough salespeople on the street. We have quite a bit less than our competitors have out there right now. So this is a matter of doing that last stage of investing. And we're on top of that. We're moving as fast as we can right now on that.

Um, I'm not expecting this channel inventory to bounce back. We're taking it out, out and we're going to manage it more aggressively to ensure stability there. But I do expect better execution. We have
a long history of strong execution, so um I'm confident in the team and that we'll deliver

Passages & reports (3)
  • at the end on the sales. We don't have enough salespeople out there. Like hindsight's 2020…
  • stage of investing. And we're on top of that. We're moving as fast as we can right now on …
  • a long history of strong execution, so um I'm confident in the team and that we'll deliver

Speaker unclear

?that.

Passages & reports (1)
  • that.

Speaker 0

Thank

Passages & reports (1)
  • Thank

Speaker unclear

?you.

Passages & reports (1)
  • you.

Speaker 0

Your next question is from the line of Steve Lichman. Please go ahead.

Passages & reports (1)
  • Your next question is from the line of Steve Lichman. Please go ahead.

Speaker unclear

?Thank you.

Passages & reports (1)
  • Thank you.

Speaker unclear

?know, and on the decision

Passages & reports (1)
  • know, and on the decision

Speaker 6

to ?to keep the business. You pointed to the valuation disconnect. ?Um, but you know, as

Passages & reports (5)
  • to
  • to keep the
  • business. You pointed to the valuation disconnect.
  • Um, but
  • you know, as

Speaker unclear

?you look at the two

Passages & reports (1)
  • you look at the two

Speaker 6

businesses together,

Passages & reports (1)
  • businesses together,

Speaker unclear

?you know, coming off of this

Passages & reports (1)
  • you know, coming off of this

Speaker 6

process, what

Passages & reports (1)
  • process, what

Speaker unclear

?was management and the board's ultimate assessment

Passages & reports (1)
  • was management and the board's ultimate assessment

Speaker 7

of why ?the two together are stronger

Passages & reports (3)
  • of why
  • the two
  • together are stronger

Speaker unclear

?than

Passages & reports (1)
  • than

Speaker 6

apart? ?Uh, because ?obviously the lack of obvious ?synergies has been one ?of the questions from investors.

Passages & reports (9)
  • apart?
  • Uh,
  • because
  • obviously the
  • lack of obvious
  • synergies
  • has been one
  • of the
  • questions from investors.

Speaker 2

Yeah,

Passages & reports (1)
  • Yeah,

Speaker 3

well, I would say that it's it's really the PL at the end of the day. Because if you take a look at

Passages & reports (1)
  • well, I would say that it's it's really the PL at the end of the day. Because if you take …

Speaker 2

the shared services concept that we've deployed, remember we did the restructuring in Q4 of last year, and you've seen the savings. I mean, I know there's frustration over revenues. I have frustration over revenues, but I think this was something like our 11th straight quarter of beating earnings expectations. And some of those quarters, we beaten earnings expectations by five, ten percent. ?I mean, we beat earnings this quarter with Cooper Vision coming in way under what revenue expectations

Passages & reports (4)
  • the shared services concept that we've deployed, remember we did the restructuring in Q4 o…
  • we beaten earnings expectations by five, ten percent.
  • I
  • mean, we beat earnings this quarter with Cooper Vision coming in way under what revenue ex…

Speaker 3

were. So the strength of the PL, when I look at it from a perspective of operating leverage and being able to drive that and drive cash flow, highest quarterly cash flow we've ever had in the company. And as Brian said, we're going to keep delivering a lot of cash flow. At the end of the day, yeah, you're right. We have two different

Passages & reports (2)
  • were. So the strength of the PL, when I look at it from a perspective of operating leverag…
  • of the day, yeah, you're right. We have two different

Speaker 2

businesses. But the back office, when it comes to finance, IT, legal, and HR, and so forth, can support very effectively both of these businesses so that we can generate good earnings and really strong cash flow. And then we need to deploy that cash flow to stock buybacks. And we did a lot of buybacks this quarter. We're going to generate a lot of cash next year,

Passages & reports (2)
  • businesses. But the back office, when it comes to finance, IT, legal, and HR, and so forth…
  • buybacks this quarter. We're going to generate a lot of cash next year,

Speaker 3

and

Passages & reports (1)
  • and

Speaker 2

that's

Passages & reports (1)
  • that's

Speaker 3

going

Passages & reports (1)
  • going

Speaker 2

to continue to be our focus. So that's where the logic comes in of having the two companies together. And proof is in the pudding, which we've done. Now we need to get revenue growth going, and I get that. Within vision, surgical is actually plugging along fine. Even through all these disruptions. I mean,

Passages & reports (1)
  • to continue to be our focus. So that's where the logic comes in of having the two companie…

Speaker 3

this was an incredibly disruptive process. Like ?we thought we were

Passages & reports (3)
  • this was an incredibly disruptive process. Like
  • we
  • thought we were

Speaker unclear

?going to sell Cooper

Passages & reports (1)
  • going to sell Cooper

Speaker 2

Surgical. Let's be clear about that. Like I got on the last call and I talked about that. Like, so everybody at this company was working on their normal jobs, on the sale of the business. Every piece of planning that we were doing, every budgeting, every IT plan had to go and have a with and without each of them and so forth. But we got through that.

We got through the exercise and we still delivered the earnings and we killed the free cash flow. And now we turn our attention back to where it needs to be, which is driving revenue growth within Cooper Vision and investing
heavier in Cooper Vision. And that's what we're going to do next. So it's one more box we need to check, and I think that's the last one that we need to check.

But that's the logic of having the businesses together.

Passages & reports (3)
  • Surgical. Let's be clear about that. Like I got on the last call and I talked about that. …
  • with and without each of them and so forth. But we got through that. We got through the ex…
  • heavier in Cooper Vision. And that's what we're going to do next. So it's one more box we …

Speaker unclear

?Got it. Great. And and and then just follow up to that in terms of use of free cash

Passages & reports (1)
  • Got it. Great. And and and then just follow up to that in terms of use of free cash

Speaker 6

looking for beyond stock buybacks. You may have mentioned this in your release tonight, but is it fair to say that relative to inorganic, that vision is is uh going to be a higher focus now than than that's on CSI LL SQL?

Passages & reports (1)
  • looking for beyond stock buybacks. You may have mentioned this in your release tonight, bu…

Speaker 3

A hundred percent, yeah. They're very heavy focus right

Passages & reports (1)
  • A hundred percent, yeah. They're very heavy focus right

Speaker 2

now on

Passages & reports (1)
  • now on

Speaker 3

Cooper Vision organic growth. Um that's where we

Passages & reports (1)
  • Cooper Vision organic growth. Um that's where we

Speaker 2

that's where we need to put our attention. That's where we are

Passages & reports (1)
  • that's where we need to put our attention. That's where we are

Speaker 3

putting our attention, and that's where we're putting our money. That doesn't mean that Cooper Surgical is not going to do well and get its

Passages & reports (1)
  • putting our attention, and that's where we're putting our money. That doesn't mean that Co…

Speaker 2

investments

Passages & reports (1)
  • investments

Speaker 3

because

Passages & reports (1)
  • because

Speaker 2

fertility is very important

Passages & reports (1)
  • fertility is very important

Speaker 3

to us and

Passages & reports (1)
  • to us and

Speaker unclear

?and

Passages & reports (1)
  • and

Speaker 2

we're strong

Passages & reports (1)
  • we're strong

Speaker 3

on the med

Passages & reports (1)
  • on the med

Speaker 2

device side,

Passages & reports (1)
  • device side,

Speaker 3

and

Passages & reports (1)
  • and

Speaker 2

we're going to continue to invest and grow those businesses. But the number one focus, clear in a way, is driving organic growth at Cooper Vision right

Passages & reports (1)
  • we're going to continue to invest and grow those businesses. But the number one focus, cle…

Speaker unclear

?now. Got it. Thanks, Al.

Passages & reports (1)
  • now. Got it. Thanks, Al.

Speaker 2

Yep.

Passages & reports (1)
  • Yep.

Speaker 0

Your next question is from the line of David Saxon. Please go ahead.

Passages & reports (1)
  • Your next question is from the line of David Saxon. Please go ahead.

Speaker 7

Great. Thanks for taking my questions. Good afternoon. Maybe one on CVI and I'll ask one on CSI as my second. So just on CVI, ?you know, a follow-up to the the sales and marketing investments. Like are there specific regions that need those additional resources? Do you need those as additional sales reps to get to the mid digits next year, and then would love to just get your your latest take on pricing and how the market's uh how you're feeling about the market's ability to take price.

Passages & reports (4)
  • Great. Thanks for taking my questions. Good afternoon. Maybe one on CVI and I'll ask one o…
  • you
  • know, a follow-up to the the sales and marketing investments. Like are there specific regi…
  • you're feeling about the market's ability to take price.

Speaker 3

Sure. So when it comes to the

Passages & reports (1)
  • Sure. So when it comes to the

Speaker 2

Salesforce expansion, I would start that with the U.S.

Passages & reports (1)
  • Salesforce expansion, I would start that with the U.S.

Speaker 3

market because right now

Passages & reports (1)
  • market because right now

Speaker 2

we

Passages & reports (1)
  • we

Speaker 3

are we're we've got consumption growing mid-single

Passages & reports (1)
  • are we're we've got consumption growing mid-single

Speaker 2

digits. That's probably in line roughly with where the market is. Um we should be doing better than that. Given the contracts we won and so forth, we should be growing faster than market here. The addition of this direct sales force and the expansion that we're doing right now is going to add coverage for something like 5,000 additional doors. So that's a big deal for us.

Do we need to get that sales force in place to get to mid-single digit? No, because that's what we're doing right now on a look-through basis. Should we be accelerating that doing better? Yes, we should be. When I look at
uh Europe, they're in good spot. I challenge the European team there. We have a great, fantastic leader running Europe over there, and I've challenged him to maybe look at some expansion and hiring some more salespeople.

Asia Pack's in pretty good shape right now. I just talked to the head of Japan, great guy,
energized. He's got some really good ideas. I really I'm excited about what he's doing. He's doing some hiring over there to focus in some different areas of the markets where we don't current currently compete. Um and he needs to keep doing that. You know, I stress that to him and the rest of the team.

Invest, drive growth. We're gonna get uh these are all high return models. Like we are going through this from a return perspective. I feel good about that. But so, anyways, that gives you a little bit of color on the worldwide side. Pricing, I would say, when I look

Passages & reports (5)
  • digits. That's probably in line roughly with where the market is. Um we should be doing be…
  • for something like 5,000 additional doors. So that's a big deal for us. Do we need to get …
  • uh Europe, they're in good spot. I challenge the European team there. We have a great, fan…
  • energized. He's got some really good ideas. I really I'm excited about what he's doing. He…
  • the team. Invest, drive growth. We're gonna get uh these are all high return models. Like …

Speaker 3

at pricing and

Passages & reports (1)
  • at pricing and

Speaker 2

when I look at product mix,

Passages & reports (1)
  • when I look at product mix,

Speaker 3

it's still

Passages & reports (1)
  • it's still

Speaker 2

pretty good in the industry. The higher price products are doing better. We see that with our competitors. We see that with products like Might A MySite, the Mighty Torx, and Multifocals, and so forth continue to perform better. So higher price products

Passages & reports (1)
  • pretty good in the industry. The higher price products are doing better. We see that with …

Speaker 3

doing better,

Passages & reports (1)
  • doing better,

Speaker 2

and there still remains a ?potential to take price. Like inflation is still out there. We see that. And there's still the potential for us to be able to take price. And we're actively looking at that right

Passages & reports (3)
  • and there still remains a
  • potential to
  • take price. Like inflation is still out there. We see that. And there's still the potentia…

Speaker unclear

?now.

Passages & reports (1)
  • now.

Speaker 7

Okay. Great. Thanks for that, Al. And then on CSI, maybe just talk about what you're seeing in terms of cycle trends, what what the outlook is going into fiscal twenty seven. And then you you mentioned Paragard competition and in um the release. So would love just an update there. I I think it that competitive launch was in August. So curious if you're seeing any impact there.

Thanks so

Passages & reports (2)
  • Okay. Great. Thanks for that, Al. And then on CSI, maybe just talk about what you're seein…
  • I I think it that competitive launch was in August. So curious if you're seeing any impact…

Speaker unclear

?much.

Passages & reports (1)
  • much.

Speaker 3

Sure. Uh on the fertility side of things, we are seeing uh a growth in cycles, and that's a positive. The other thing we're seeing is we're we're hurtling through that year period where we have some consolidation,

Passages & reports (1)
  • Sure. Uh on the fertility side of things, we are seeing uh a growth in cycles, and that's …

Speaker 2

and you're starting to see fertility clinics investing more. There's more capital equipment opportunities out there. Um our genomics team is absolutely killing it. They're doing a great job taking a whole bunch of market share. We have a somewhat of a new fertility team that started probably six, twelve months ago that is really doing that. Our new leader, she's just fantastic, and she's doing a great job and killing it.

So I'm super optimistic about the fertility market. Anyone who thinks that that's not a good market or that that litigation settlement is going to disrupt our momentum and progress is just wrong. I just don't see that
in the market. When you look at the Periguard competition, we've talked about that in the past. There, we are the only Paraguard is the only non-hormonal IUD in the market right now.

There is a competitive product that that received approval that was bought, that uh uh it
closed during this past quarter for us. They started their training, um, and that product will get launched at some point in the future, and and there's concern about that. And at this point in time, I'm gonna hold off giving any guidance or commentary above and beyond what we've already given.

But we'll certainly
have a lot more color to be able to give on the December call.

Passages & reports (5)
  • and you're starting to see fertility clinics investing more. There's more capital equipmen…
  • doing that. Our new leader, she's just fantastic, and she's doing a great job and killing …
  • in the market. When you look at the Periguard competition, we've talked about that in the …
  • closed during this past quarter for us. They started their training, um, and that product …
  • have a lot more color to be able to give on the December call.

Speaker 7

Great, thank

Passages & reports (1)
  • Great, thank

Speaker unclear

?you.

Passages & reports (1)
  • you.

Speaker 2

Yep.

Passages & reports (1)
  • Yep.

Speaker 0

Your next question comes from the line of Navantai. Please go ahead.

Passages & reports (1)
  • Your next question comes from the line of Navantai. Please go ahead.

Speaker 6

Hi, thank

Passages & reports (1)
  • Hi, thank

Speaker 0

you for taking

Passages & reports (1)
  • you for taking

Speaker unclear

?my questions.

Passages & reports (1)
  • my questions.

Speaker 6

Um just on

Passages & reports (1)
  • Um just on

Speaker unclear

?the CSI post-strategic review, we've

Passages & reports (1)
  • the CSI post-strategic review, we've

Speaker 6

mentioned some insights from that review. So can you maybe discuss that in more into more detail and and the levers that you mentioned, including investment that you started ?in the quarter to drive fertility growth, if you could give more details. Thank

Passages & reports (3)
  • mentioned some insights from that review. So can you maybe discuss that in more into more …
  • in
  • the quarter to drive fertility growth, if you could give more details. Thank

Speaker unclear

?you.

Passages & reports (1)
  • you.

Speaker 3

Nirvana it was a little difficult to hear. I think you were asking for the impact of or the did you say the impact from the strategic review tied to CSI? Can you repeat your question?

Passages & reports (1)
  • Nirvana it was a little difficult to hear. I think you were asking for the impact of or th…

Speaker 6

Yeah, I think I'll mention that you gained

Passages & reports (1)
  • Yeah, I think I'll mention that you gained

Speaker 0

some insight from the strategic review

Passages & reports (1)
  • some insight from the strategic review

Speaker unclear

?and also mention some investment

Passages & reports (1)
  • and also mention some investment

Speaker 6

that you started in the quarter to drive fertility growth. If you could discuss that into more detail.

Passages & reports (1)
  • that you started in the quarter to drive fertility growth. If you could discuss that into …

Speaker 3

Sure. So the insights is an important one because one of the things that the

Passages & reports (1)
  • Sure. So the insights is an important one because one of the things that the

Speaker 2

strategic review did was to really drill down into the profitability of our portfolio, all aspects of our portfolio, frankly, and uh take a look at profitability by product and take a look at profitability by geography and relationship. One of the areas where we've seen significant improvement is that is the profitability of Cooper Surgical. And what it did is it kind of highlighted other areas where there's some some opportunity for us to do a better job in terms of driving ongoing profitability improvement.

So we're going to learn from that. Like we learned a lot from the strategic review. It uncovered some
different things, and it's going to make us a better company. It is making us a better company today. I mean, right now we are doing investments within fertility. We've added some investment activity, including within RD. We have a great new ?uh head of RD who's running that organization and pulling forward some launches.

We've got some exciting stuff going in genomics there with some new launches and some expanded products that we have. So uh I would say we're continuing that's where we're putting dollars. We're putting number one first and foremost is Cooper Vision, organic
growth, and number two, though, after that is fertility, where we are we are continuing to invest. And we believe that those investments are going to drive

Passages & reports (6)
  • strategic review did was to really drill down into the profitability of our portfolio, all…
  • is the profitability of Cooper Surgical. And what it did is it kind of highlighted other a…
  • different things, and it's going to make us a better company. It is making us a better com…
  • uh
  • head of RD who's running that organization and pulling forward some launches. We've got so…
  • growth, and number two, though, after that is fertility, where we are we are continuing to…

Speaker 3

good fertility

Passages & reports (1)
  • good fertility

Speaker 2

growth. And we also believe that some of the stuff that we've uncovered in the insights is going to give us opportunity to continue to drive leverage in that business.

Passages & reports (1)
  • growth. And we also believe that some of the stuff that we've uncovered in the insights is…

Speaker 0

Thank you. And you also mentioned the ?um in the press release the valuation impact of the fertility settlement. Is that fully settled or is there anything

Passages & reports (3)
  • Thank you. And you also mentioned the
  • um in
  • the press release the valuation impact of the fertility settlement. Is that fully settled …

Speaker 6

else we ?should know about?

Passages & reports (3)
  • else we
  • should
  • know about?

Speaker 2

That is

Passages & reports (1)
  • That is

Speaker 3

fully settled. Um so there's nothing new on that.

Passages & reports (1)
  • fully settled. Um so there's nothing new on that.

Speaker 2

There was concern that that settlement that you'll remember that was from uh uh an issue we had in 2023. There was a concern that that settlement would negatively impact our ongoing um sales, not our operations. We haven't had any issues since then associated with with the media and so forth. So um I just don't believe that's accurate and we haven't seen that.

We didn't see it in Q two, we didn't see it in Q three, we're certainly not seeing it as we get rolling here in Q four. But but I appreciate whether that was a true concern and a negotiating tactics, hard to hard
to tell.

Passages & reports (3)
  • There was concern that that settlement that you'll remember that was from uh uh an issue w…
  • I just don't believe that's accurate and we haven't seen that. We didn't see it in Q two, …
  • to tell.

Speaker 6

Thank

Passages & reports (1)
  • Thank

Speaker unclear

?you.

Passages & reports (1)
  • you.

Speaker 0

Your next question is from the line of Anthony Patron. Please go ahead.

Passages & reports (1)
  • Your next question is from the line of Anthony Patron. Please go ahead.

Speaker unclear

?Hey there,

Passages & reports (1)
  • Hey there,

Speaker 7

you have Brad

Passages & reports (1)
  • you have Brad

Speaker 3

Bowers on. For

Passages & reports (1)
  • Bowers on. For

Speaker unclear

?Anthony, uh

Passages & reports (1)
  • Anthony, uh

Speaker 4

just maybe wanted ?to ask one about the the overall strategy

Passages & reports (3)
  • just maybe wanted
  • to ask one
  • about the the overall strategy

Speaker 3

or dynamics you know underlying the CVI business. Obviously, slowdown and growth is is not unique to to Cooper, but still growing, you know, below growth we got into des stocking dynamics, but obviously you would also take in some share in some of the wider SKU ranges and you know, obviously some of the new products with uh you know the my day, uh you know, it sounds like the America's growth is strong, but you know, you even admit you wish you were growing better.

So wanted to hear about

Passages & reports (2)
  • or dynamics you know underlying the CVI business. Obviously, slowdown and growth is is not…
  • new products with uh you know the my day, uh you know, it sounds like the America's growth…

Speaker unclear

?you know some of the

Passages & reports (1)
  • you know some of the

Speaker 7

more competitive dynamics and you know the confidence that those remain you know in your favor.

Passages & reports (1)
  • more competitive dynamics and you know the confidence that those remain you know in your f…

Speaker 2

I

Passages & reports (1)
  • I

Speaker 3

I would say

Passages & reports (1)
  • I would say

Speaker 2

that those remain in our favor. So nothing has changed with with respect to that. I will say that the area where ?uh losing share is the wrong word, but where we don't operate is kind of in the super premium segment. There's a there's a part of the market, especially on the daily side, that we refer to as super premium. It's really high price products.

Um, and that's just not an area that we compete in
right now. Um, and that's shown a lot of growth, and it has a it has very high revenue per patient. So where we continue to do well, we continue to wear win patients, um, our revenue per patient is not close to where some of our competitors are. And a lot of the market continues to get driven by that really premium segment.

Now we are launching we've launched My Day My Site into that more premium segment. That's what's being launched into Europe. So I think there's some potential for us to gain some ground there. But that would be if I had to highlight two things, that
would be one of them is not having products in the super premium space. And then the other one would be the desire to rationalize some of our legacy hydrogel products.

Like and we're s we're definitely seeing the negative impact from

Passages & reports (6)
  • that those remain in our favor. So nothing has changed with with respect to that. I will s…
  • uh
  • losing share is the wrong word, but where we don't operate is kind of in the super premium…
  • right now. Um, and that's shown a lot of growth, and it has a it has very high revenue per…
  • continues to get driven by that really premium segment. Now we are launching we've launche…
  • would be one of them is not having products in the super premium space. And then the other…

Speaker unclear

?that. Oh sure, that makes

Passages & reports (1)
  • that. Oh sure, that makes

Speaker 3

sense. But but obviously, you know, punching above your weight given you know the under investment in the

Passages & reports (1)
  • sense. But but obviously, you know, punching above your weight given you know the under in…

Speaker 3

smaller sales force than competition. Obviously that that is a tailwind, but just wanted to hear, you know, maybe remind us you know how productivity kind of ramps there. ?You know, obviously the base is now lower,

Passages & reports (3)
  • smaller sales force than competition. Obviously that that is a tailwind, but just wanted t…
  • You
  • know, obviously the base is now lower,

Speaker 2

so it does kind of imply getting back towards that you know high, you know, mid to even high single digits, you know, to your point, getting

Passages & reports (1)
  • so it does kind of imply getting back towards that you know high, you know, mid to even hi…

Speaker unclear

?above consumption. Um, and then also

Passages & reports (1)
  • above consumption. Um, and then also

Speaker 2

just yet impact obviously apparent. Maybe the opportunity that that would be obscured, you know, if there is strong growth in the US by some of

Passages & reports (1)
  • just yet impact obviously apparent. Maybe the opportunity that that would be obscured, you…

Speaker 7

the OUS impacts, just maybe ?help us figure

Passages & reports (3)
  • the OUS impacts, just maybe
  • help
  • us figure

Speaker unclear

?that out as well.

Passages & reports (1)
  • that out as well.

Speaker 2

Thank ?you. Sure. Just uh one quick point, because Brian just said that yeah, I'm at My

Passages & reports (3)
  • Thank
  • you.
  • Sure. Just uh one quick point, because Brian just said that yeah, I'm at My

Speaker 3

Day Energist.

Passages & reports (1)
  • Day Energist.

Speaker 2

I think I said my day my site, but my day energist is the premium product. Um With the Salesforce, I would

Passages & reports (1)
  • I think I said my day my site, but my day energist is the premium product. Um With the Sal…

Speaker 3

say if I had to

Passages & reports (1)
  • say if I had to

Speaker 2

put some

Passages & reports (1)
  • put some

Speaker 3

parameters

Passages & reports (1)
  • parameters

Speaker 2

around that, we're recruiting now, we'll get people trained and have them out on the street executing. I would say probably in early, mid fiscal Q2. So from that perspective, right, they need to visit offices and start doing start doing their jobs and so forth and pulling revenues in. So that's probably a positive impact more in the Q3, Q4 timeframe. Now I do think early in the year we'll continue to have consumption be solid, so it will still put up good results, but I but I believe we'll accelerate a little bit off that as we get the benefit from those employees.

Frankly, same thing when I look at some of the other markets around the world.

Passages & reports (3)
  • around that, we're recruiting now, we'll get people trained and have them out on the stree…
  • revenues in. So that's probably a positive impact more in the Q3, Q4 timeframe. Now I do t…
  • those employees. Frankly, same thing when I look at some of the other markets around the w…

Speaker 0

Your next question is from the line of Brett Fishbin. Please go ahead.

Passages & reports (1)
  • Your next question is from the line of Brett Fishbin. Please go ahead.

Speaker unclear

?lot of mine have

Passages & reports (1)
  • lot of mine have

Speaker 7

been asked. So maybe just a follow-up on ?kind of the last point. I I was gonna ask about your thoughts on underlying market share dynamics, just given the full year CBI growth guide for the Americas. ?Um, it sounds like a lot of it has to do ?with Salesforce and you know, you're looking at some incremental investment activity. So so maybe just the first part, is there anything else that stands out that you think might be driving, call it full year growth in the Americas below market outside of that?

And then the the second follow-up question is just how you're
feeling about the product portfolio. I think your point about super premium lenses is really interesting. So just just curious like how you feel ?about current offerings and maybe how active the RD pipeline might be in regards to some new ideas or or even new brands. Thank you so

Passages & reports (10)
  • been asked. So maybe just a follow-up on
  • kind
  • of the last point. I I was gonna ask about your thoughts on underlying market share dynami…
  • Um,
  • it sounds like a lot of it has to do
  • with
  • Salesforce and you know, you're looking at some incremental investment activity. So so may…
  • feeling about the product portfolio. I think your point about super premium lenses is real…
  • about
  • current offerings and maybe how active the RD pipeline might be in regards to some new ide…

Speaker unclear

?much.

Passages & reports (1)
  • much.

Speaker 4

Sure.

Passages & reports (1)
  • Sure.

Speaker 3

I would say on the

Passages & reports (1)
  • I would say on the

Speaker 2

on

Passages & reports (1)
  • on

Speaker 3

the uh

Passages & reports (1)
  • the uh

Speaker 2

selling side I would go back to sales execution. Like we've won ?some great private label contracts here in the U.S. with a few of the buying groups. We've won some really nice contracts in Asia Pack. Historically, when we win those contracts, we would see the sales execution turn those into revenue growth. And that's what we've expected more of that, right? You've seen that in some of the guidance.

You've seen it in some of my commentary. That's where that has not come to fruition yet. And where when we looked at it and peeled back the onion and said, well, why? What is the difference? What's happening? We have a full portfolio out there right now. I feel good about
the four po the portfolio. It's arguably the most robust that we've ever had, and we didn't build out the sales force and a lot of the marketing support commensurate with the size of the portfolio that we have right now.

So we needed to
?we need to do this activity so we can capitalize on these contract wins that we have. I will say with respect to our RD and new products, um we have accelerated that activity. We've had a number of meetings uh with the R D team and with our uh commercial team. We are accelerating launch activity that we were looking at in the 2030 kind of time frame and pulling that forward a couple years.

So very, very active on RD and laser focusing in on some new product introductions that we think are going to be pretty damn exciting. We were a little too broad on some things, so
narrowing that down and uh executing and getting some new products into the marketplace is going to be beneficial for us. And ?I won't go too far on that yet, but we will spend some time in the in the nearer future going through some of those details.

Passages & reports (11)
  • selling side I would go back to sales execution. Like we've won
  • some
  • great private label contracts here in the U.S. with a few of the buying groups. We've won …
  • of the guidance. You've seen it in some of my commentary. That's where that has not come t…
  • the four po the portfolio. It's arguably the most robust that we've ever had, and we didn'…
  • we
  • need to do this activity so we can capitalize on these contract wins that we have. I will …
  • activity that we were looking at in the 2030 kind of time frame and pulling that forward a…
  • narrowing that down and uh executing and getting some new products into the marketplace is…
  • I
  • won't go too far on that yet, but we will spend some time in the in the nearer future goin…

Speaker unclear

?All

Passages & reports (1)
  • All

Speaker 7

right, awesome. Thanks so much. I'll keep it to one question, but look forward to hearing more about that in the next few years. Thanks so

Passages & reports (1)
  • right, awesome. Thanks so much. I'll keep it to one question, but look forward to hearing …

Speaker unclear

?much.

Passages & reports (1)
  • much.

Speaker 2

Yep. Thanks, Brad.

Passages & reports (1)
  • Yep. Thanks, Brad.

Speaker 0

And our final question comes from the line of Izzy Kirby. Please go ahead. Hey,

Passages & reports (1)
  • And our final question comes from the line of Izzy Kirby. Please go ahead. Hey,

Speaker 6

thanks for squeezing me in. I think most of mine have been asked as well, but just wanted to touch on Asia Pacific and China in particular, which has been a drag for for quite some time now. Can you remind us of the size of that business for you guys in Vision and just how you're thinking about it strategically? Like, does it get to a point where it's really, ?you know, given this the dynamics in the market, uh, not necessarily worth you being there anymore?

Thanks.

Passages & reports (4)
  • thanks for squeezing me in. I think most of mine have been asked as well, but just wanted …
  • how you're thinking about it strategically? Like, does it get to a point where it's really…
  • you
  • know, given this the dynamics in the market, uh, not necessarily worth you being there any…

Speaker 3

Yeah, well, China was another struggle this quarter. Um, I mean, it was the only market as

Passages & reports (1)
  • Yeah, well, China was another struggle this quarter. Um, I mean, it was the only market as

Speaker 2

an

Passages & reports (1)
  • an

Speaker 3

example where my

Passages & reports (1)
  • example where my

Speaker 2

site

Passages & reports (1)
  • site

Speaker 3

was actually

Passages & reports (1)
  • was actually

Speaker 2

down. Um, it's not it has not been a great market for us. So we are re-engineering there. We've got a new team in place. We're looking at some different growth opportunities to see the best way to reestablish and drive growth in that marketplace right now. I do believe that I will say within the context of Asia Pack, after many quarters of negatives and product rationalization in China and some of the other markets, we are definitely coming to an end with that activity.

I know you heard that before, but I'll just tell you when you look at the size of the business, I mean
it's gotten to be um it's just relatively small. I mean I think it's less than two percent it is less than two percent of revenues this quarter on a consolidated basis. So the business just is getting smaller over there. So yeah it's a great question and a great challenge and and we are looking at seeing if we can reinvigorate that business to drive success and I do believe there's some opportunities there in some channels like e commerce where we can play differently and be successful.

uh we're taking a hard look at it right now because we want to get um
?uh good revenues, if you will, right? Profitable revenues and things that make sense. So doing work on it. That's and I'll update you more as as we get into December and give guidance on next

Passages & reports (6)
  • down. Um, it's not it has not been a great market for us. So we are re-engineering there. …
  • say within the context of Asia Pack, after many quarters of negatives and product rational…
  • it's gotten to be um it's just relatively small. I mean I think it's less than two percent…
  • looking at seeing if we can reinvigorate that business to drive success and I do believe t…
  • uh
  • good revenues, if you will, right? Profitable revenues and things that make sense. So doin…

Speaker unclear

?year. Thanks so much. Can I just really quickly squeeze in a

Passages & reports (1)
  • year. Thanks so much. Can I just really quickly squeeze in a

Speaker 6

follow-up on on what went on with my site in China in in the quota?

Passages & reports (1)
  • follow-up on on what went on with my site in China in in the quota?

Speaker 2

Sure. We have not been able to gain traction with my site in China. And if I look around the world and other markets that have spectacles, we continue to do fine. As a matter of fact, it just grows the overall marketplace. I think the unique thing with China ends up being Orth OK, probably more than anything. You've had a lot of pricing pressure on orth okay because of government uh pricing uh policies, so it's really disrupted that marketplace.

There's a lot of knockoffs there. There's a lot of disruption around pricing with Orth OK. There's a lot of knockoff spectacle lenses and so forth there.

Passages & reports (2)
  • Sure. We have not been able to gain traction with my site in China. And if I look around t…
  • probably more than anything. You've had a lot of pricing pressure on orth okay because of …

So, although there's massive opportunity with the number of children that that have myopia, um, the market itself is is very disjointed right now.

Passages & reports (1)
  • So, although there's massive opportunity with the number of children that that have myopia…

Speaker unclear

?Thanks so much.

Passages & reports (1)
  • Thanks so much.

Speaker 2

Yeah.

Passages & reports (1)
  • Yeah.

Speaker 0

And with no further questions, thank you. I will now turn the call back over for closing remarks.

Passages & reports (1)
  • And with no further questions, thank you. I will now turn the call back over for closing r…

Speaker 3

Uh thank you, operator, and thank you, everyone, for taking the time. Uh, I know we had a lot to discuss today, and I'm sure we'll have a lot of follow-up up calls with details, so I appreciate uh everyone's interest and look forward to catching up and uh and uh providing an update on our next earnings call in December. Thank

Passages & reports (2)
  • Uh thank you, operator, and thank you, everyone, for taking the time. Uh, I know we had a …
  • our next earnings call in December. Thank

Speaker unclear

?you.

Passages & reports (1)
  • you.

Speaker 0

Thank you again for joining us today. This does conclude today's conference call. You may now disconnect.

Passages & reports (1)
  • Thank you again for joining us today. This does conclude today's conference call. You may …
Source, accuracy & exportsMay contain errorsAccuracy unmeasured. Speakers are anonymous voice labels, local to this call. No names are verified. Section starts and timestamps are inferred. Speakers are anonymous voice labels, local to this call. No names are verified. Section starts and timestamps are inferred.

Short unclear spans may appear inline between matching voice IDs. The ? marker retains unknown attribution; no voice identity is inferred for those words.

AI-generated transcript; names, numbers and wording may be inaccurate.

Speaker IDs are anonymous and local to this call. Section boundaries and timestamps are inferred.

The diarizer reached its eight-speaker limit; distinct voices may share an ID.

Zero-duration alignments: 0. Unassigned words: 235. No alignment has been repaired. Timestamps locate passages in the source recording; decimal positions do not establish word-level precision.

Official issuer source ↗ · Report an issue

Published transcript · Full recording available. Publication updated 2026-11-16T02:22:56.080Z.
Transcript version v1-60fca6b1772d8851a537 · publication revision 1. Generated by AI; no listener-verified accuracy score is available.

Dotted spans marked ? have an unclear speaker. They remain unattributed even when shown inside a surrounding turn.

Copy or download
ReadableGrouped by speaker and paragraph with timestamps. Stored words unchanged.
As storedOne line per stored segment with its original speaker ID and start time. Exactly the stored words.
Official issuer source ↗Company overview ↗
TRANSCRIPT FEEDBACK

Report a passage

Your report is queued privately for review. It does not change this transcript automatically. Please avoid personal information.